Articles

Several baseline factors were associated with an increased risk for early treatment discontinuation in the phase 3 monarchE clinical trial, which assessed adjuvant abemaciclib (Verzenio) in patients with hormone receptor–positive, HER2-negative early breast cancer, according to findings from a multivariate analysis presented during the 2022 American Society of Clinical Oncology Annual Meeting. Read More ›

The addition of pembrolizumab (Keytruda) to chemotherapy with or without bevacizumab (Avastin) resulted in significantly and clinically meaningful improvements in overall survival (OS) and progression-free survival (PFS) in women with cervical cancer. Read More ›

Immune checkpoint inhibitor therapy in advanced biliary tract cancer (BTC) is associated with limited clinical activity. Read More ›

During a session at the Cholangiocarcinoma (CCA) Foundation 2022 annual meeting, Dr Zachariah H. Foda from the Johns Hopkins School of Medicine discussed the role of circulating tumor DNA (ctDNA) in early detection and disease monitoring for CCA. Read More ›

When clinicians and patients rely on different terminology for the term “cure” in cancer treatment, it can lead to patient dissatisfaction and confusion. Read More ›

Next-generation sequencing at initial workup of the patient with advanced non–small-cell lung cancer can shorten time between diagnosis and treatment and may improve survival. Read More ›

Recent study found that the use of sotorasib after anti–PD-L1 therapy in patients with NSCLC increased the chance of severe adverse events and liver toxicity. Read More ›

Patients with non–small-cell lung cancer with a history of prior radiotherapy before immune checkpoint inhibitor treatment are at increased risk for developing severe pneumonitis. Read More ›

This section provides a brief overview of new cancer drugs and new indications approved by the FDA between October 21, 2021, and November 14, 2022. Read More ›

Miami Cancer Institute at Baptist Health South Florida offers patients with cancer cutting-edge, personalized therapy as well as a myriad of comprehensive services. Read More ›